AIMS: To determine the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator (ICD) patients by combining results from published trials. METHODS AND RESULTS: We searched in the Medline, EMBASE, and Cochrane databases and performed a meta-analysis on all three available trials on fish oil and ventricular arrhythmia. Furthermore, we pooled individual data of two of these randomized, double-blind, placebo-controlled trials (Raitt et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-2891 and Brouwer et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-2619). The main outcome was time to first confirmed ventricular fibrillation (VF) or ventricular tachycardia (VT) combined with death for the meta-analysis, and time to first spontaneous confirmed VF or VT for the pooled analysis. The meta-analysis (n = 1148) showed no convincing protective effect of fish oil (RR 0.90; 95% CI 0.67-1.22). The hazard ratio for the subgroup of patients with coronary artery disease at baseline (0.79; 0.60-1.06) tended towards a protective effect. The pooled analysis (n = 722) showed that time to appropriate ICD intervention was similar for fish oil and placebo treatment (log-rank P = 0.79). CONCLUSION: These findings do not support a protective effect of omega-3 PUFAs from fish oil on cardiac arrhythmia in all patients with an ICD. Current data neither prove nor disprove a beneficial or a detrimental effect for subgroups of patients with specific underlying pathologies.
AIMS: To determine the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator (ICD) patients by combining results from published trials. METHODS AND RESULTS: We searched in the Medline, EMBASE, and Cochrane databases and performed a meta-analysis on all three available trials on fish oil and ventricular arrhythmia. Furthermore, we pooled individual data of two of these randomized, double-blind, placebo-controlled trials (Raitt et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-2891 and Brouwer et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-2619). The main outcome was time to first confirmed ventricular fibrillation (VF) or ventricular tachycardia (VT) combined with death for the meta-analysis, and time to first spontaneous confirmed VF or VT for the pooled analysis. The meta-analysis (n = 1148) showed no convincing protective effect of fish oil (RR 0.90; 95% CI 0.67-1.22). The hazard ratio for the subgroup of patients with coronary artery disease at baseline (0.79; 0.60-1.06) tended towards a protective effect. The pooled analysis (n = 722) showed that time to appropriate ICD intervention was similar for fish oil and placebo treatment (log-rank P = 0.79). CONCLUSION: These findings do not support a protective effect of omega-3 PUFAs from fish oil on cardiac arrhythmia in all patients with an ICD. Current data neither prove nor disprove a beneficial or a detrimental effect for subgroups of patients with specific underlying pathologies.
Authors: Ka He; Yiqing Song; Martha L Daviglus; Kiang Liu; Linda Van Horn; Alan R Dyer; Philip Greenland Journal: Circulation Date: 2004-06-08 Impact factor: 29.690
Authors: M L Burr; A M Fehily; J F Gilbert; S Rogers; R M Holliday; P M Sweetnam; P C Elwood; N M Deadman Journal: Lancet Date: 1989-09-30 Impact factor: 79.321
Authors: M L Burr; P A L Ashfield-Watt; F D J Dunstan; A M Fehily; P Breay; T Ashton; P C Zotos; N A A Haboubi; P C Elwood Journal: Eur J Clin Nutr Date: 2003-02 Impact factor: 4.016
Authors: Rozenn N Lemaitre; Irena B King; Dariush Mozaffarian; Lewis H Kuller; Russell P Tracy; David S Siscovick Journal: Am J Clin Nutr Date: 2003-02 Impact factor: 7.045
Authors: D S Siscovick; T E Raghunathan; I King; S Weinmann; K G Wicklund; J Albright; V Bovbjerg; P Arbogast; H Smith; L H Kushi Journal: JAMA Date: 1995-11-01 Impact factor: 56.272
Authors: Lidia Daimiel-Ruiz; Mercedes Klett-Mingo; Valentini Konstantinidou; Victor Micó; Juan F Aranda; Belén García; Javier Martínez-Botas; Alberto Dávalos; Carlos Fernández-Hernando; Jose M Ordovás Journal: Mol Nutr Food Res Date: 2015-01-21 Impact factor: 5.914
Authors: George E Billman; Yoshinori Nishijima; Andriy E Belevych; Dmitry Terentyev; Ying Xu; Kaylan M Haizlip; Michelle M Monasky; Nitisha Hiranandani; William S Harris; Sandor Gyorke; Cynthia A Carnes; Paul M L Janssen Journal: Am J Physiol Heart Circ Physiol Date: 2010-01-22 Impact factor: 4.733